



GIG  
CYMRU  
NHS  
WALES

Bwrdd Iechyd Prifysgol  
Cwm Taf Morgannwg  
University Health Board



## Freedom of Information Request: Our Reference CTMUHB\_253\_25

### You asked:

I am analysing the usage of new biologic and targeted medications within dermatology medicine. Could you please answer the following question:

1. How many patients were treated in May 2025 (or latest available month) by the Dermatology department with the following drugs:

- Abrocitinib (Cibinqo)
- Baricitinib (Olumiant)
- Dupilumab (Dupixent)
- Lebrikizumab (Ebglyss)
- Omalizumab (Xolair)
- Tralokinumab (Adtralza)
- Upadacitinib (Rinvoq)
- Nemolizumab (Nemluvio)

2. How many patients were treated in May 2025 (or latest available month) by the Respiratory Medicine departments with the following drugs:

- Benralizumab (Fasenra)
- Dupilumab (Dupixent)
- Mepolizumab (Nucala)
- Omalizumab (Xolair)
- Reslizumab (Cinqaero)
- Tezepelumab (Tezspire)

### Our response:

Please find below a table providing information in relation to questions 1 and 2 that Medicines Management are able to provide at this current time. The period the data relates to May 2025 as requested.

Where the figures are less than 5, this has been denoted by \*\*. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This

exemption is absolute and therefore there is no requirement to apply the public interest test.

<b>Medicine</b>	<b>Number of Patients Dermatology</b>	<b>Number of Patients Respiratory</b>
Abrocitinib (Cibinqo)	**	0
Baricitinib (Olumiant)	**	0
Benralizumab (Fasenra)	0	18
Dupilumab (Dupixent)	110	0
Lebrikizumab (Ebglyss)	7	0
Mepolizumab (Nucala)	0	41
Nemolizumab (Nemluvio)	0	0
Omalizumab (Xolair)	43	9
Reslizumab (Cinqaero)	0	0
Tezepelumab (Tezspire)	0	34
Tralokinumab (Adtralza)	8	0
Upadacitinib (Rinvoq)	**	0